Regeneron (REGN) said Saturday that Libtayo reduced the risk of recurrence or death by 68% in post-surgical high-risk cutaneous squamous cell carcinoma, meeting the phase 3 C-POST trial's primary endpoint.

The immunotherapy also cut the risk of locoregional and distant recurrence by 80% and 65%, respectively, the company said.

Median disease-free survival was not reached in the Libtayo group versus 49 months for placebo, with two-year disease-free survival rates of 87% and 64%, respectively, Regeneron said.

The company said adverse events of grade 3 or higher occurred in 24% of Libtayo patients versus 14% for placebo, treatment discontinuation due to adverse events was 10% in the Libtayo arm.

Regulatory applications for adjuvant use of Libtayo have been submitted in the US and EU, Regeneron added.